What is Leerink Partnrs’ Estimate for AMLX Q1 Earnings?

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) – Investment analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for Amylyx Pharmaceuticals in a report issued on Sunday, April 13th. Leerink Partnrs analyst M. Goodman anticipates that the company will earn ($0.52) per share for the quarter. The consensus estimate for Amylyx Pharmaceuticals’ current full-year earnings is ($2.20) per share. Leerink Partnrs also issued estimates for Amylyx Pharmaceuticals’ Q2 2025 earnings at ($0.51) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.49) EPS, FY2026 earnings at ($1.75) EPS, FY2027 earnings at ($1.70) EPS and FY2028 earnings at ($1.40) EPS.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its earnings results on Tuesday, March 4th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.06). The business had revenue of ($0.67) million during the quarter.

A number of other equities analysts have also recently commented on AMLX. HC Wainwright reissued a “buy” rating and issued a $12.00 price target on shares of Amylyx Pharmaceuticals in a research note on Wednesday, March 5th. Mizuho raised Amylyx Pharmaceuticals from a “neutral” rating to an “outperform” rating and increased their target price for the company from $3.00 to $7.00 in a research note on Monday, April 7th. Two analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $8.00.

Amylyx Pharmaceuticals Trading Down 1.5 %

Shares of NASDAQ AMLX opened at $3.82 on Wednesday. The business has a 50-day moving average of $3.55 and a 200-day moving average of $4.09. The firm has a market capitalization of $338.46 million, a price-to-earnings ratio of -1.00 and a beta of -0.53. Amylyx Pharmaceuticals has a 12 month low of $1.58 and a 12 month high of $7.27.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the company. FMR LLC raised its stake in shares of Amylyx Pharmaceuticals by 292.0% during the third quarter. FMR LLC now owns 221,001 shares of the company’s stock valued at $716,000 after acquiring an additional 164,622 shares during the last quarter. Barclays PLC raised its position in Amylyx Pharmaceuticals by 91.1% during the 3rd quarter. Barclays PLC now owns 84,572 shares of the company’s stock valued at $274,000 after purchasing an additional 40,319 shares during the last quarter. Geode Capital Management LLC raised its position in Amylyx Pharmaceuticals by 17.5% during the 3rd quarter. Geode Capital Management LLC now owns 551,039 shares of the company’s stock valued at $1,786,000 after purchasing an additional 82,173 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in Amylyx Pharmaceuticals by 144.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 140,559 shares of the company’s stock worth $455,000 after buying an additional 83,048 shares during the period. Finally, Blue Trust Inc. increased its stake in shares of Amylyx Pharmaceuticals by 232.1% during the fourth quarter. Blue Trust Inc. now owns 6,987 shares of the company’s stock valued at $26,000 after buying an additional 4,883 shares during the period. Hedge funds and other institutional investors own 95.84% of the company’s stock.

Insider Buying and Selling

In related news, CEO Joshua B. Cohen sold 11,851 shares of the stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $3.47, for a total transaction of $41,122.97. Following the completion of the sale, the chief executive officer now directly owns 3,201,247 shares in the company, valued at $11,108,327.09. This represents a 0.37 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Bernhardt G. Zeiher purchased 10,000 shares of the firm’s stock in a transaction on Thursday, March 20th. The stock was bought at an average cost of $3.70 per share, for a total transaction of $37,000.00. Following the completion of the purchase, the director now directly owns 10,000 shares in the company, valued at approximately $37,000. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 64,509 shares of company stock worth $222,586 in the last 90 days. 11.70% of the stock is owned by company insiders.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.